- Iron-deficiency anemia in paediatric patients with inflammatory bowel disease (IBD) can be safely and effectively treated with intravenous iron sucrose (IVIS).
Why this matters
- IVIS is safe and effective for treating adults but is not well studied in children.
- Researchers analysed the health records of patients aged
- They defined efficacy as ≥2 g/dL increase in Hb ≤12 weeks from IVIS initiation.
- Funding: None.
- Adverse events occurred in 6 patients; none developed anaphylaxis.
- Efficacy evaluations included 80 IVIS courses and showed that 58.7% (47) of courses resulted in goal haemoglobin (Hgb) increases.
- Mean Hb rise was 9.1±1.4 to 11.9±1.8 g/dL (P<.0001 paired t-test>
- The study was retrospective and exploratory.
- Some efficacy and minor adverse event data were missing or incomplete.